Fennec Pharmaceuticals Inc. FENC
Institutional shares held
14.7 Million
10K
calls
83.8K
puts
Total value of holdings
$96.9M
$65K
calls
$552K
puts
Market Cap
$172M
26,067,300
Shares Out.
Institutional ownership
56.43%
# of Institutions
64
We take great care to ensure that the data presented and summarized in this overview for FENNEC PHARMACEUTICALS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FENC
View all-
Southpoint Capital Advisors LP New York, NY4.08MShares$26.9 Million0.71% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$15.9 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$14.8 Million11.1% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.82 Million0.0% of portfolio
-
Dg Capital Management, LLC New York, NY1.11MShares$7.35 Million2.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$6.39 Million0.0% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL467KShares$3.08 Million1.53% of portfolio
-
Morgan Stanley New York, NY346KShares$2.28 Million0.0% of portfolio
-
State Street Corp Boston, MA340KShares$2.24 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA303KShares$2 Million0.0% of portfolio
Latest Institutional Activity in FENC
Top Purchases
Top Sells
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Transactions at FENC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-12.7%
|
$60,000
$6.79 P/Share
|
|
Feb 28
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+3.0%
|
-
|
|
Feb 28
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.79%
|
-
|
|
Feb 14
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,186
-2.19%
|
$7,116
$6.82 P/Share
|
|
Feb 14
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
1,992
+3.54%
|
$3,984
$2.51 P/Share
|
|
Feb 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-11.59%
|
$60,000
$6.66 P/Share
|
|
Jan 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+2.74%
|
-
|
|
Jan 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.79%
|
-
|
|
Jan 06
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-5.43%
|
$60,000
$6.08 P/Share
|
|
Dec 31
2024
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+2.52%
|
-
|
|
Dec 31
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.8%
|
-
|
|
Dec 20
2024
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+21.47%
|
$50,000
$2.69 P/Share
|
|
Dec 05
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
796
-1.18%
|
$4,776
$6.04 P/Share
|
|
Dec 03
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
1,635
-2.37%
|
$9,810
$6.13 P/Share
|
|
Dec 02
2024
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+3.41%
|
-
|
|
Dec 02
2024
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
6,409
-10.93%
|
$38,454
$6.14 P/Share
|
|
Dec 02
2024
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.57%
|
$20,000
$2.69 P/Share
|
|
Dec 02
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.8%
|
-
|
|
Nov 18
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,816
+11.04%
|
$31,632
$2.45 P/Share
|
|
Nov 04
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
2,431
-3.53%
|
$9,724
$4.31 P/Share
|
Last 12 Months Summary
Buy / Acquisition
275K
Shares
From
9
Insiders
| Exercise of conversion of derivative security | 107K shares |
|---|---|
| Grant, award, or other acquisition | 38.2K shares |
| Open market or private purchase | 41.7K shares |
| Open market or private sale | 88.9K shares |
Sell / Disposition
448K
Shares
From
5
Insiders
| Open market or private sale | 353K shares |
|---|---|
| Bona fide gift | 95K shares |